{"generic":"Imiquimod","drugs":["Aldara","Imiquimod","Zyclara"],"mono":{"0":{"id":"924239-s-0","title":"Generic Names","mono":"Imiquimod"},"1":{"id":"924239-s-1","title":"Dosing and Indications","sub":{"0":{"id":"924239-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>2.5% and 3.75% cream:<\/b> Safety and efficacy have not been established for treatment of immunosuppressed patients; superficial basal cell carcinoma; xeroderma pigmentosum; urethral, intravaginal, cervical, rectal or intra-anal human papilloma viral disease<\/li><li><b>5% cream:<\/b> Safety and efficacy have not been established in immunosuppressed patients and patients with autoimmune conditions, xeroderma pigmentosum, or basal cell nevus syndrome<\/li><li><b>Actinic keratosis:<\/b> 2.5% and 3.75% cream: Apply up to 2 packets or 2 full pump actuations TOPICALLY to entire affected area on the face or balding scalp every day at bedtime for 2 weeks, followed by no treatment for 2 weeks, and then another 2 weeks of treatment; leave the cream on the skin for approximately 8 hours, then wash the area with mild soap and water; full treatment course should be completed regardless of resolution of actinic keratoses or tolerable skin reactions; temporary increases in number of lesions may be experienced; evaluate response to treatment only after all local skin reactions have resolved; re-evaluate unresponsive lesions and reconsider treatment plan<\/li><li><b>Actinic keratosis:<\/b> 5% cream: Apply TOPICALLY to defined treatment area 2 times per week at bedtime for 16 weeks; leave on skin for 8 hours<\/li><li><b>Condyloma acuminatum, External:<\/b> 3.75% cream: Apply up to 1 packet or 1 pump actuation TOPICALLY to warts once daily at bedtime until total clearance or for up to 8 weeks; leave on skin for 8 hours, then wash area with mild soap and water<\/li><li><b>Condyloma acuminatum, External:<\/b> 5% cream: Apply TOPICALLY to affected area 3 times per week until total clearance or up to a MAX duration of 16 weeks; apply at bedtime and leave on skin for 6 to 10 hours<\/li><li><b>Condyloma acuminatum, External - HIV infection:<\/b> 5% cream: Apply TOPICALLY to lesion at bedtime 3 times per week on nonconsecutive nights for up to 16 weeks; wash with soap and water 6 to 10 hours after each application (guideline dosing)<\/li><li><b>Superficial basal cell carcinoma, on trunk, neck, or extremities; when surgical methods are less appropriate and follow-up is assured:<\/b> 5% cream: Apply TOPICALLY once daily 5 times per week for 6 weeks; apply at bedtime and leave on skin for 8 hours<\/li><li><b>Superficial basal cell carcinoma, on trunk, neck, or extremities; when surgical methods are less appropriate and follow-up is assured:<\/b> 5% cream: Tumors 0.5 cm to less than 1 cm in diameter, apply a 4 mm diameter cream droplet (10 mg); tumors 1 cm to less than 1.5 cm in diameter, apply a 5 mm diameter cream droplet (25 mg); tumors 1.5 cm to 2 cm in diameter, apply a 7 mm cream droplet (40 mg of cream)<\/li><\/ul>"},"1":{"id":"924239-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy have not been established in pediatric patients in the treatment of immunosuppressed patients; superficial basal cell carcinoma; xeroderma pigmentosum; urethral, intravaginal, cervical, rectal or intra-anal human papilloma viral disease<\/li><li><b>Condyloma acuminatum, External:<\/b> 3.75% cream (12 years or older): Apply up to 1 packet or 1 pump actuation TOPICALLY to warts once daily at bedtime until total clearance or for up to 8 weeks; leave on skin for 8 hours, then wash area with mild soap and water<\/li><li><b>Condyloma acuminatum, External:<\/b> 5% cream (12 years or older): Apply TOPICALLY to affected area 3 times per week until total clearance or up to a MAX duration of 16 weeks; apply at bedtime and leave on skin for 6 to 10 hours<\/li><li><b>Condyloma acuminatum, External - HIV infection:<\/b> 5% cream: Apply TOPICALLY to lesion at bedtime 3 times per week on nonconsecutive nights for up to 16 weeks; wash with soap and water 6 to 10 hours after each application (guideline dosing)<\/li><\/ul>"},"3":{"id":"924239-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Actinic keratosis<\/li><li>Condyloma acuminatum, External<\/li><li>Superficial basal cell carcinoma, on trunk, neck, or extremities; when surgical methods are less appropriate and follow-up is assured<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Condyloma acuminatum, External - HIV infection<br\/>"}}},"3":{"id":"924239-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924239-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"924239-s-3-10","title":"Precautions","mono":"<ul><li>autoimmune conditions, preexisting<\/li><li>concomitant use with condoms or vaginal diaphragms not recommended<\/li><li>inflammatory conditions of the skin, including chronic graft versus host disease; may exacerbate<\/li><li>inflammation of female genitalia, including vulvar swelling; may occur leading to urinary retention; therapy interruption or discontinuation may be necessary if severe<\/li><li>local inflammatory reaction (skin weeping or erosion) may occur; therapy interruption or discontinuation may be necessary<\/li><li>sexual contact, genital, anal, or oral; should be avoided during use<\/li><li>sunburn preexisting; do not initiate therapy until healed<\/li><li>sunlight exposure, including sunlamps, avoid or minimize; protect skin from sunlight exposure to prevent serious sunburn; if sunburn occurs, hold therapy until completely healed<\/li><li>systemic reactions including flu-like symptoms (malaise, fever, nausea, myalgias, rigors) may accompany or precede local inflammatory reaction; consider therapy interruption<\/li><li>unhealed skin due to previous drug or surgical treatments; use is not recommended until healed<\/li><li>report suspected adverse reactions to Graceway Pharmaceuticals, LLC at 1-800-328-0255 or to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924239-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924239-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"924239-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Application site reaction (28% to 33%), Edematous skin (41% to 78%), Erythema (all grades, 96% to 100%; severe grade, 18% to 31%), Peeling of skin (88% to 93%), Pruritus (16% to 32%), Scab of skin (79% to 93%), Sensation of burning of skin (6% to 26%), Skin discharge (22% to 51%), Skin ulcer (36% to 62%)<\/li><li><b>Immunologic:<\/b>Influenza-like symptoms (up to 4%)<\/li><li><b>Neurologic:<\/b>Headache (2% to 8%)<\/li><li><b>Respiratory:<\/b>Upper respiratory infection (3% to 15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia, Heart failure, Henoch-Schoenlein purpura, Myocardial infarction, Syncope<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Erythroderma<\/li><li><b>Hematologic:<\/b>Idiopathic thrombocytopenic purpura<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Reproductive:<\/b>Genital edema, female<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"924239-s-6","title":"Drug Name Info","sub":{"0":{"id":"924239-s-6-17","title":"US Trade Names","mono":"<ul><li>Aldara<\/li><li>Zyclara<\/li><\/ul>"},"2":{"id":"924239-s-6-19","title":"Class","mono":"Immune Modulator<br\/>"},"3":{"id":"924239-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924239-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"924239-s-7","title":"Mechanism Of Action","mono":"The mechanism of action of imiquimod in the treatment of actinic keratosis, superficial basal cell carcinomas, and external genital warts is unknown. With topical application to the skin, imiquimod activates immune cells through Toll-like receptor 7, leading to increased markers for cytokines and immune cells.<br\/>"},"8":{"id":"924239-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924239-s-8-23","title":"Absorption","mono":"Tmax: approximately 9 hours <br\/>"},"3":{"id":"924239-s-8-26","title":"Excretion","mono":"Renal: 0.08% to 2.41% <br\/>"},"4":{"id":"924239-s-8-27","title":"Elimination Half Life","mono":"20 to 24.1 hours <br\/>"}}},"9":{"id":"924239-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>not for oral, ophthalmic, intravaginal use<\/li><li>not for intra-anal use<\/li><\/ul><\/li><li><b>Topical<\/b><br\/><ul><li>Apply a thin layer to affected areas at bedtime and rub until cream is no longer visible; do not use occlusive dressings.<\/li><li>Wash hands before and after application.<\/li><li>(3.75% cream) 7.5 and 15 g bottles: Prime pump before first use<\/li><li>(Actinic keratosis): Avoid contact with or use near eyes, lips, and nostrils; following each treatment period of 8 hours, remove imiquimod cream by washing the treated area with soap and water.<\/li><li>(Actinic keratosis, 5% cream): Single-use packets contain sufficient cream to cover a 25 cm(2) treatment area on either the face or scalp.<\/li><li>(Actinic keratosis, 2.5% and 3.75% cream): Up to 2 packets or 2 pump actuations of cream may be necessary.<\/li><li>(Actinic keratosis, 2.5% and 3.75% cream): Intolerable skin reactions may require several treatment-free days; treatment cycles should not be extended due to missed doses or treatment-free days.<\/li><li>(Actinic keratosis, 2.5% and 3.75% cream): No more than 56 packets, two 7.5-g pumps, or one 15-g pump for the total treatment course should be prescribed; discard unused and partially used packets.<\/li><li>(External genital warts): Avoid contact with or use in anus or vagina.<\/li><li>(External genital warts, 5% cream): Apply prior to normal sleeping hours; leave on the skin for 6 to 10 hours.<\/li><li>(External genital warts, 3.75% cream): Apply prior to normal sleeping hours; leave on the skin for 8 hours.<\/li><li>(External genital warts, 3.75% cream): Intolerable skin reactions may require several, treatment-free days; once the reaction resolves, restart treatment; cotton gauze or cotton underwear may be used in the management of skin reactions.<\/li><li>(External genital warts, 3.75% cream): No more than 56 packets, two 7.5-g pumps, or one 15-g pump for the total treatment course should be prescribed; discard unused and partially-used packets.<\/li><li>(Superficial basal carcinoma, 5% cream): Apply prior to normal sleeping hours; leave on the skin for 8 hours and then wash off with mild soap and water; application should include 1 cm margin of skin around the tumor; amount of cream is based on the diameter of the target tumor.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"924239-s-10","title":"Monitoring","mono":"symptomatic improvement (reduction in wart size)<br\/>"},"11":{"id":"924239-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Topical Cream: 5 %<br\/><\/li><li><b>Aldara<\/b><br\/>Topical Cream: 5 %<br\/><\/li><li><b>Zyclara<\/b><br\/>Topical Cream: 2.5 %, 3.75 %<br\/><\/li><\/ul>"},"13":{"id":"924239-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to use only one imiquimod cream on the treated area to avoid risk of more severe local or systemic reactions. Imiquimod is available as Aldara(R) and Zyclara(R).<\/li><li>Drug may cause phototoxicity. Advise patient to minimize exposure to natural and artificial light, and to use protective clothing and sunscreen.<\/li><li>Warn patient treating genital warts to avoid sex (genital, anal, or oral) during treatment. The cream may weaken condoms and vaginal diaphragms.<\/li><li>Advise patient to report vulvar swelling. Therapy should be interrupted or discontinued with severe vulvar swelling as it may lead to urinary retention.<\/li><li>This drug may cause edema, erythema, vesicles, ulcerations, weeping, flaking, scaling, dryness, or crusting of the skin.<\/li><li>Advise patient treated skin may have localized hypopigmentation or hyperpigmentation that may be permanent.<\/li><li>Instruct patient to report severe local reactions or systemic flu-like symptoms (malaise, fever, or myalgia).<\/li><li>Advise patient that imiquimod is not a cure for genital warts and that new warts may develop during treatment.<\/li><li>Tell patient not to use occlusive dressings over treated areas.<\/li><\/ul>"}}}